Faculty Opinions recommendation of Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727683217.793533460 ◽

2017 ◽

Author(s):

Aleix Prat

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30376-5 ◽

2017 ◽

Vol 18 (7) ◽

pp. 904-916 ◽

Cited By ~ 248

Author(s):

José Baselga ◽

Seock-Ah Im ◽

Hiroji Iwata ◽

Javier Cortés ◽

Michele De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30688-5 ◽

2018 ◽

Vol 19 (1) ◽

pp. 87-100 ◽

Cited By ~ 151

Author(s):

Angelo Di Leo ◽

Stephen Johnston ◽

Keun Seok Lee ◽

Eva Ciruelos ◽

Per E Lønning ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Mtor Inhibition ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Download Full-text

Chidamide Plus Exemestane for Postmenopausal Patients with Hormone-Receptor-Positive Advanced Breast Cancer (ACE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3327363 ◽

2019 ◽

Author(s):

Zefei Jiang ◽

Wei Li ◽

Xichun Hu ◽

Qingyuan Zhang ◽

Tao Sun ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive ◽

Ace Study

Download Full-text

Faculty Opinions recommendation of Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732279400.793559076 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Mtor Inhibition ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Download Full-text

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(16)32389-3 ◽

2016 ◽

Vol 388 (10063) ◽

pp. 2997-3005 ◽

Cited By ~ 212

Author(s):

John F R Robertson ◽

Igor M Bondarenko ◽

Ekaterina Trishkina ◽

Mikhail Dvorkin ◽

Lawrence Panasci ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase 3 ◽

Double Blind ◽

Hormone Receptor Positive

Download Full-text

Faculty Opinions recommendation of Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718355395.793494247 ◽

2014 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

European Journal of Cancer ◽

10.1016/j.ejca.2015.10.012 ◽

2016 ◽

Vol 53 ◽

pp. 144-154 ◽

Cited By ~ 19

Author(s):

Konstantinos Tryfonidis ◽

Gul Basaran ◽

Jan Bogaerts ◽

Marc Debled ◽

Luc Dirix ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

European Organisation ◽

Hormone Receptor Positive

Download Full-text

Abstract OT3-2-10: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) ± goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy

10.1158/0008-5472.sabcs13-ot3-2-10 ◽

2013 ◽

Cited By ~ 2

Author(s):

N Turner ◽

F André ◽

S Loibl ◽

J Ro ◽

H Iwata ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Controlled Trial ◽

Metastatic Breast ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Hormone Receptor Positive

Download Full-text

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70138-x ◽

2014 ◽

Vol 15 (6) ◽

pp. 580-591 ◽

Cited By ~ 281

Author(s):

Fabrice André ◽

Ruth O'Regan ◽

Mustafa Ozguroglu ◽

Masakazu Toi ◽

Binghe Xu ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Her2 Positive ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Patients’ preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments

SpringerPlus ◽

10.1186/s40064-015-1482-9 ◽

2015 ◽

Vol 4 (1) ◽

Cited By ~ 6

Author(s):

Surachat Ngorsuraches ◽

Klangjai Thongkeaw

Keyword(s):

Breast Cancer ◽

Willingness To Pay ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Cancer Treatments ◽

Postmenopausal Hormone ◽

Hormone Receptor Positive

Download Full-text